For more information, or to report problems registering, please contact The Exeter Group at 1-800-532-1344 (North America only) or +1-212-644-1017.

Supported by an educational grant from sanofi–aventis

Pre-registration is now closed.
Please register for the meeting on-site.

Faculty

A. John Camm, MD

Chair

Professor of Clinical Cardiology

Division of Cardiac and Vascular Sciences

St. George’s University of London

London, England, United Kingdom

Stuart J. Connolly, MD

Director, Division of Cardiology

Professor, Department of Medicine

McMaster University

Hamilton Health Sciences

Hamilton, Ontario, Canada

Peter R. Kowey, MD

Professor of Medicine and Clinical Pharmacology

Jefferson Medical College

Philadelphia, Pennsylvania

Chief, Division of Cardiovascular Diseases

Main Line Health System

The William Wikoff Smith Chair in Cardiovascular Research

Lankenau Hospital and Medical Research Center

Wynnewood, Pennsylvania, United States

David J. Wilber, MD

George M. Eisenberg Professor of Cardiovascular Sciences

Director, Cardiovascular Institute

Division Director, Cardiology

Department of Medicine

Loyola University Chicago — Stritch School of Medicine

Medical Director, Clinical Electrophysiology

Loyola University Health System

Maywood, Illinois, United States

 

This event is not part of the official ACC Annual Scientific Session and/or the ACC’s Innovation in Intervention: i2 Summit in Partnership with the Cardiovascular Research Foundation, as planned by their Program Committees.

Agenda

6:00 – 6:45 pm
Registration and dinner

6:45 – 8:45 pm
Scientific program

Welcome and introduction

A. John Camm

Defining the goals of therapy in AF

A. John Camm

The expanding clinical potential of novel antiarrhythmic agents

Stuart J. Connolly

Approaching ablation in AF: The critical considerations

David J. Wilber

Has the balance shifted in the rate- vs. rhythm-control debate?

Peter R. Kowey

Panel discussion / Q & A

Moderator: A. John Camm

Closing remarks

A. John Camm

 

Target audience

This activity is intended for cardiologists and other healthcare professionals caring for patients with nonvalvular atrial fibrillation (AF).

 

Educational objectives

At the completion of this activity, the participants should be able to:

  • Define the specific goals of AF therapy in different clinical circumstances, with particular reference to patient age, underlying or concomitant disease such as congestive heart failure, and risk of stroke
  • Assess the role of novel antiarrhythmic agents in AF, both in terms of improving symptomatology and reducing the incidence of adverse clinical outcomes
  • Outline criteria for selecting patients best suited for catheter ablation of AF
  • Summarize the rate-vs.-rhythm–control debate and discuss whether new approaches to rhythm control militate in its favor
  • Maximize net clinical benefit in the management of patients with nonvalvular AF.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and The Exeter Group.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.

Physicians should only claim credits commensurate with the extent of their participation.

The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturers.

The University of Cincinnati is committed to retaining only those speakers with financial interests that can be resolved and reconciled with the goals and educational integrity of the CME program.